Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

David A. Wilcox PhD

David A. Wilcox PhD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology


Publications

  • In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection. (Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q) J Thromb Haemost 2014 Jun 16: PMID 24931217
  • High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. (Sullivan SK, Mills JA, Koukouritaki SB, Vo KK, Lyde RB, Paluru P, Zhao G, Zhai L, Sullivan LM, Wang Y, Kishore S, Gharaibeh EZ, Lambert MP, Wilcox DA, French DL, Poncz M, Gadue P) Blood 2014 Jan 30;123(5):753-7 PMID 24335497
  • Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. (Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA) Nat Commun 2013;4:2773 PMID 24253479
  • Glanzmann thrombasthenia: state of the art and future directions. (Nurden AT, Pillois X, Wilcox DA) Semin Thromb Hemost 2013 Sep;39(6):642-55 PMID 23929305
  • Arachidonic acid-induced dilation in human coronary arterioles: convergence of signaling mechanisms on endothelial TRPV4-mediated Ca2+ entry. (Zheng X, Zinkevich NS, Gebremedhin D, Gauthier KM, Nishijima Y, Fang J, Wilcox DA, Campbell WB, Gutterman DD, Zhang DX) J Am Heart Assoc 2013 Jun;2(3):e000080 PMID 23619744
  • C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. (Fang J, Nurden P, North P, Nurden AT, Du LM, Valentin N, Wilcox DA) J Thromb Haemost 2013 Jun;11(6):1163-71 PMID 23551977
  • Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. (Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q) J Thromb Haemost 2012 Aug;10(8):1570-80 PMID 22632092
  • Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. (Fang J, Jensen ES, Boudreaux MK, Du LM, Hawkins TB, Koukouritaki SB, Cornetta K, Wilcox DA) Proc Natl Acad Sci U S A 2011 Jun 7;108(23):9583-8 PMID 21606353
  • Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. (Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ) Blood 2011 May 5;117(18):4946-52 PMID 21368290
  • TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. (Mendoza SA, Fang J, Gutterman DD, Wilcox DA, Bubolz AH, Li R, Suzuki M, Zhang DX) Am J Physiol Heart Circ Physiol 2010 Feb;298(2):H466-76 PMID 19966050
  • Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. (Ghevaert C, Wilcox DA, Fang J, Armour KL, Clark MR, Ouwehand WH, Williamson LM) J Clin Invest 2008 Aug;118(8):2929-38 PMID 18654666
  • Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. (Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR) Blood 2008 Oct 1;112(7):2713-21 PMID 18495954
  • Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. (Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR) J Thromb Haemost 2007 Feb;5(2):352-61 PMID 17269937
  • Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. (Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR) J Clin Invest 2006 Jul;116(7):1974-82 PMID 16823491
  • Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. (Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA) Blood 2005 Oct 15;106(8):2671-9 PMID 15972454
  • Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. (Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR) J Thromb Haemost 2004 Nov;2(11):1989-97 PMID 15550031
  • Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. (Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR) J Thromb Haemost 2003 Dec;1(12):2477-89 PMID 14675082
  • Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation. (Niemeyer GP, Boudreaux MK, Goodman-Martin SA, Monroe CM, Wilcox DA, Lothrop CD Jr) Exp Hematol 2003 Dec;31(12):1357-62 PMID 14662345
  • Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. (Wilcox DA, White GC 2nd) J Thromb Haemost 2003 Nov;1(11):2300-11 PMID 14629461
  • Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. (Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M) Blood 2003 Dec 1;102(12):4006-13 PMID 12881300
  • Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. (Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR) Mol Genet Metab 2003 May;79(1):25-33 PMID 12765843
  • Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. (Wilcox DA, Olsen JC, Ishizawa L, Bray PF, French DL, Steeber DA, Bell WR, Griffith M, White GC 2nd) Blood 2000 Jun 15;95(12):3645-51 PMID 10845892
  • Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. (Shiraga M, Ritchie A, Aidoudi S, Baron V, Wilcox D, White G, Ybarrondo B, Murphy G, Leavitt A, Shattil S) J Cell Biol 1999 Dec 27;147(7):1419-30 PMID 10613901
  • Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. (Wilcox DA, Olsen JC, Ishizawa L, Griffith M, White GC 2nd) Proc Natl Acad Sci U S A 1999 Aug 17;96(17):9654-9 PMID 10449749
  • Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. (Wilcox DA, Paddock CM, Lyman S, Gill JC, Newman PJ) J Clin Invest 1995 Apr;95(4):1553-60 PMID 7706461
  • A single amino acid substitution flanking the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin complex. (Wilcox DA, Wautier JL, Pidard D, Newman PJ) J Biol Chem 1994 Feb 11;269(6):4450-7 PMID 7508443
  • Developing neural crest cells in culture: correlation of cytochrome oxidase activity with SSEA-1 and dopamine-beta-hydroxylase immunoreactivity. (Liu S, Wilcox DA, Sieber-Blum M, Wong-Riley M) Brain Res 1990 Dec 10;535(2):271-80 PMID 1981490
  • Grants and Awards

  • Therapeutic-Expresssion of Platelet-Specific Integrin (#9204757 08/01/2007 - 06/30/2012) Sponsor: NIH Heart Lung and Blood Institute
  • Platelet-Specific Gene Therapy and Its Potential For Correcting Hemophilia (#9204807 07/01/2007 - 06/30/2009) Sponsor: American Heart Association Wisconsin